NEFL and myeloid sarcoma: Indeed, metabolomics and NfL levels may be utilized in a complementary manner—metabolomics as an early tool to detect newly developing clinically silent neuroinflammation, with NfL as a latter marker to confirm neuroaxonal injury, providing a holistic surrogate for MS lesions throughout their evolution.